Nasopharyngeal carcinoma-associated Epstein-Barr virus-encoded oncogene latent membrane protein 1 potentiates regulatory T-cell function

Immunology and Cell Biology

Volumn 85, Issue 5, 2007, Pages 370-377

  Pai, Saparna ^a,b   O'Sullivan, Brendan ^a   Abdul Jabbar, Ibtissam ^a   Peng, Judy ^a   Connoly, Geoff ^b   Khanna, Rajiv ^b   Thomas, Ranjeny ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

EBV latent membrane protein 1; Immunoregulation; Interleukin 10; NF B; Regulatory T cell

Indexed keywords

INTERLEUKIN 10; LATENT MEMBRANE PROTEIN 1;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; EPSTEIN BARR VIRUS; GENETIC TRANSFECTION; HELPER CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; MIXED LYMPHOCYTE REACTION; NASOPHARYNX CARCINOMA; REGULATORY T LYMPHOCYTE;

ANTIGEN-PRESENTING CELLS; ANTIGENS, CD4; B-LYMPHOCYTES; CELL LINE; CELL NUCLEUS; CELL PROLIFERATION; HUMANS; INTERLEUKIN-10; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MUTATION; NASOPHARYNGEAL NEOPLASMS; NF-KAPPA B; PROTEIN TRANSPORT; T-LYMPHOCYTES, REGULATORY; TRANSFECTION; VIRAL MATRIX PROTEINS;

HUMAN HERPESVIRUS 4;

EID: 34447134183     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/sj.icb.7100046     Document Type: Article

References (51)

1. Miller G, Niederman JC, Stitt DA. Infectious mononucleosis: appearance of neutralizing antibody to Epstein-Barr virus measured by inhibition of formation of lymphoblastoid cell lines. J Infect Dis 1972; 125: 403-406.
2. Huen DS, Henderson SA, Croom-Carter D, Rowe M. The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 1995; 10: 549-560.
3. Devergne O, Cahir McFarland ED, Mosialos G, Izumi KM, Ware CF, Kieff E. Role of the TRAF binding site and NF-kappaB activation in Epstein-Barr virus latent membrane protein 1-induced cell gene expression. J Virol 1998; 72: 7900-7908.
4. Izumi KM, Kieff ED. The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-kappaB. Proc Natl Acad Sci USA 1997; 94: 12592-12597.
5. Pai S, O'Sullivan BJ, Cooper L, Thomas R, Khanna R. RelB nuclear translocation mediated by C-terminal activator regions of Epstein-Barr virus-encoded latent membrane protein 1 and its effect on antigen-presenting function in B cells. J Virol 2002; 76: 1914-1921.
6. Trivedi P, Hu LF, Chen F, Christensson B, Masucci MG, Klein G et al. Epstein-Barr virus (EBV)-encoded membrane protein LMP1 from a nasopharyngeal carcinoma is non-immunogenic in a murine model system, in contrast to a B cell-derived homologue. Eur J Cancer 1994; 30A: 84-88.
7. Hu LF, Chen F, Zheng X, Ernberg I, Cao SL, Christensson B et al. Clonability and tumorigenicity of human epithelial cells expressing the EBV encoded membrane protein LMP1. Oncogene 1993; 8: 1575-1583.
8. Sakaguchi S. Regulatory T cells: key controllers of immunologic self tolerance. Cell 2000; 101: 455-458.
9. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 1151-1164.
10. Yamazaki S, Iyoda T, Tarbell K, Olson K, Velinzon K, Inaba K et al. Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J Exp Med 2003; 198: 235-247.
11. Aandahl EM, Michaelsson J, Moretto WJ, Hecht FM, Nixon DF. Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J Virol 2004; 78: 2454-2459.
12. Marshall NA, Vickers MA, Barker RN. Regulatory T cells secreting IL-10 dominate the immune response to EBV latent membrane protein 1. J Immunol 2003; 170: 6183-6189.
13. Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, McGavern DB, Oldstone MB. Interleukin-10 determines viral clearance or persistence in vivo. Nat Med 2006; 12: 1301-1309.
14. Ejrnaes M, Filippi CM, Martinic MM, Ling EM, Togher LM, Crotty S et al. Resolution of a chronic viral infection after interleukin-10 receptor blockade. J Exp Med 2006; 203: 2461-2472.
15. O'Sullivan BJ, Thomas R. CD40 Ligation conditions dendritic cell antigen-presenting function through sustained activation of NF-kappaB. J Immunol 2002; 168: 5491-5498.
16. Rowe M, Khanna R, Jacob CA, Argaet V, Kelly A, Powis S et al. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up- regulation of peptide transporters and HLA-class I antigen expression. Eur J Immunol 1995; 25: 1374-1384.
17. Blake SM, Eliopoulos AG, Dawson CW, Young LS. The transmembrane domains of the EBV-encoded latent membrane protein 1 (LMP1) variant CAO regulate enhanced signalling activity. Virology 2001; 282: 278-287.
18. Dieckmann D, Bruett CH, Ploettner H, Lutz MB, Schuler G. Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells [corrected]. J Exp Med 2002; 196: 247-253.
19. + T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000; 192: 1213-1222.
20. Zheng SG, Wang JH, Gray JD, Soucier H, Horwitz DA. Natural and induced CD4+CD25+ cells educate CD4+CD25- cells to develop suppressive activity: the role of IL-2, TGF-beta, and IL-10. J Immunol 2004; 172: 5213-5221.
21. Dieckmann D, Plottner H, Dotterweich S, Schuler G. Activated CD4+ CD25+ T cells suppress antigen-specific CD4+ and CD8+ T cells but induce a suppressive phenotype only in CD4+ T cells. Immunology 2005; 115: 305-314.
22. Stassen M, Fondel S, Bopp T, Richter C, Muller C, Kubach J et al. Human CD25+ regulatory T cells: two subsets defined by the integrins alpha 4 beta 7 or alpha 4 beta 1 confer distinct suppressive properties upon CD4+ T helper cells. Eur J Immunol 2004; 34: 1303-1311.
23. Nakagomi H, Dolcetti R, Bejarano MT, Pisa P, Kiessling R, Masucci MG. The Epstein-Barr virus latent membrane protein-1 (LMP1) induces interleukin-10 production in Burkitt lymphoma lines. Int J Cancer 1994; 57: 240-244.
24. Vockerodt M, Haier B, Buttgereit P, Tesch H, Kube D. The Epstein-Barr virus latent membrane protein 1 induces interleukin-10 in Burkitt's lymphoma cells but not in Hodgkin's cells involving the p38/SAPK2 pathway. Virology 2001; 280: 183-198.
25. O'Sullivan BJ, MacDonald KP, Pettit AR, Thomas R. RelB nuclear translocation regulates B cell MHC molecule, CD40 expression, and antigen-presenting cell function. Proc Natl Acad Sci USA 2000; 97: 11421-11426.
26. Cherney BW, Sgadari C, Kanegane C, Wang F, Tosato G. Expression of the Epstein-Barr virus protein LMP1 mediates tumor regression in vivo. Blood 1998; 91: 2491-2500.
27. Hu LF, Chen F, Zhen QF, Zhang YW, Luo Y, Zheng X et al. Differences in the growth pattern and clinical course of EBV-LMP1 expressing and non-expressing nasopharyngeal carcinomas. Eur J Cancer 1995; 31A: 658-660.
28. Pai S, Khanna R. Role of LMP1 in immune control of EBV infection. Semin Cancer Biol 2001; 11: 455-460.
29. Dukers DF, Meij P, Vervoort MB, Vos W, Scheper RJ, Meijer CJ et al. Direct immunosuppressive effects of EBV-encoded latent membrane protein 1. J Immunol 2000; 165: 663-670.
30. de Waal Malefyt R, Yssel H, De Vries JE. Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells. J Immunol 1993; 150: 4754-4765.
31. Taga K, Mostowski H, Tosato G. Human interleukin-10 can directly inhibit T-cell growth. Blood 1993; 81: 2964-2971.
32. Bejarano MT, de Waal Malefyt R, Abrams JS, Bigler M, Bacchetta R, de Vries JE et al. Interleukin 10 inhibits allogeneic proliferative and cytotoxic T cell responses generated in primary mixed lymphocyte cultures. Int Immunol 1992; 4: 1389-1397.
33. Groux H, Cottrez F, Rouleau M, Mauze S, Antonenko S, Hurst S et al. A transgenic model to analyze the immunoregulatory role of IL-10 secreted by antigen-presenting cells. J Immunol 1999; 162: 1723-1729.
34. Clerici M, Wynn TA, Berzofsky JA, Blatt SP, Hendrix CW, Sher A et al. Role of interleukin-10 in T helper cell dysfunction in asymptomatic individuals infected with the human immunodeficiency virus. J Clin Invest 1994; 93: 768-775.
35. Landay AL, Clerici M, Hashemi F, Kessler H, Berzofsky JA, Shearer GM. In vitro restoration of T cell immune function in human immunodeficiency virus-positive persons: effects of interleukin (IL)-12 and anti-IL-10. J Infect Dis 1996; 173: 1085-1091.
36. Rigopoulou EI, Abbott WG, Haigh P, Naoumov NV. Blocking of interleukin-10 receptor - a novel approach to stimulate T-helper cell type 1 responses to hepatitis C virus. Clin Immunol 2005; 117: 57-64.
37. Brooks DG, McGavern DB, Oldstone MB. Reprogramming of antiviral T cells prevents inactivation and restores T cell activity during persistent viral infection. J Clin Invest 2006; 116: 1675-1685.
38. Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000; 192: 1213-1222.
39. Chen ZM, O'Shaughnessy MJ, Gramaglia I, Panoskaltsis-Mortari A, Murphy WJ, Narula S et al. IL-10 and TGF-beta induce alloreactive CD4+CD25- T cells to acquire regulatory cell function. Blood 2003; 101: 5076-5083.
40. Levings MK, Gregori S, Tresoldi E, Cazzaniga S, Bonini C, Roncarolo MG. Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells. Blood 2005; 105: 1162-1169.
41. Saraiva M, Christensen JR, Tsytsykova AV, Goldfeld AE, Ley SC, Kioussis D et al. Identification of a macrophage-specific chromatin signature in the IL-10 locus. J Immunol 2005; 175: 1041-1046.
42. Oldenhove G, de Heusch M, Urbain-Vansanten G, Urbain J, Maliszewski C, Leo O et al. CD4+ CD25+ regulatory T cells control T helper cell type 1 responses to foreign antigens induced by mature dendritic cells in vivo. J Exp Med 2003; 198: 259-266.
43. Zheng Y, Vig M, Lyons J, Van Parijs L, Beg AA. Combined deficiency of p50 and cRel in CD4+ T cells reveals an essential requirement for nuclear factor kappaB in regulating mature T cell survival and in vivo function. J Exp Med 2003; 197: 861-874.
44. Martin E, O'Sullivan B, Low P, Thomas R. Antigen-specific suppression of a primed immune response by dendritic cells mediated by regulatory T cells secreting interleukin-10. Immunity 2003; 18: 155-167.
45. Mainou BA, Raab-Traub N. LMP1 strain variants: biological and molecular properties. J Virol 2006; 80: 6458-6468.
46. Gandhi MK, Lambley E, Duraiswamy J, Dua U, Smith C, Elliott S et al. Expression of LAG-3 by tumor-infiltrating lymphocytes is co-incident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients. Blood 2006; 108: 2280-2289.
47. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003; 198: 1875-1886.
48. Green S, Issemann I, Sheer E. A versatile in vivo and in vitro eukaryotic expression vector for protein engineering. Nucleic Acids Res 1988; 16: 369.
49. Hu LF, Zabarovsky ER, Chen F, Cao SL, Ernberg I, Klein G et al. Isolation and sequencing of the Epstein-Barr virus BNLF-1 gene (LMP1) from a Chinese nasopharyngeal carcinoma. J Gen Virol 1991; 72 (Part 10): 2399-2409.
50. Pettit AR, Quinn C, MacDonald KP, Cavanagh LL, Thomas G, Townsend W et al. Nuclear localization of RelB is associated with effective antigen- presenting cell function. J Immunol 1997; 159: 3681-3691.
51. Cavanagh LL, Saal RJ, Grimmett KL, Thomas R. Proliferation in monocyte-derived dendritic cell cultures is caused by progenitor cells capable of myeloid differentiation. Blood 1998; 92: 1598-1607.